go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Abbott Laboratories Ireland Limited

Abbott Laboratories Ireland Limited
4051 Kingswood Drive, Citywest Business Campus, Dublin 24,
Telephone: +353 1 469 1500
Fax: +353 1 469 1501
Summary of Product Characteristics last updated on medicines.ie: 17/11/2011
SPC Chirocaine 0.625mg/ml and 1.25mg/ml Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
Date of revision of text on the SPC:   10-Nov-2011
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company

Updates to SPC sections 4.4, 4.8 & 5.1.
Updated on 23/07/2010 and displayed until 17/11/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
Date of revision of text on the SPC:   15-Jul-2010
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company


  • In section 4.4 (special warnings and precautions for use), addition of the statement 'Levobupicacaine can cause acute allergic reactions, cardiovascular effects and neurological damage, see section 4.8'
  • In section 4.8 (undesirable effects), update to include certain preferred terms into the tablet which are currently located underneath the table
  • Updated on 05/10/2009 and displayed until 23/07/2010
    Reasons for adding or updating:
    • Change to section 2 - Qualitative and quantitative composition
    • Change to section 4.4 - Special warnings and precautions for use
    • Change to section 4.8 - Undesirable effects
    • Change to section 6.3 - Shelf life
    Date of revision of text on the SPC:   18-Sep-2009
    Legal Category:   Product subject to medical prescription which may not be renewed (A)

    Free-text change information supplied by the pharmaceutical company

    
    • In Section 2 - A statement regarding the level of Sodium in the product has been added.
    • In Section 4.4 - A warning for Sodium content has been placed in this section.
    • In section 4.8 -  The section has been reformatted to MedDRA system order class and frequency.
    • In Section 6.3 - This section has been updated to show a clearer definition of shelf life for reconstituted product and the product itself.
    Updated on 21/05/2007 and displayed until 05/10/2009
    Reasons for adding or updating:
    • Change to section 4.8 - Undesirable effects
    • Addition of joint SPC covering all presentations
    Date of revision of text on the SPC:   04/2007
    Legal Category:   prescription only

    Free-text change information supplied by the pharmaceutical company

    Change to section 4.8 - Undesirable effects
    Change to joint SPC covering all presentations 
     
    Updated on 19/12/2006 and displayed until 21/05/2007
    Reasons for adding or updating:
    • Change to section 6.3 - Shelf life
    • Improved electronic presentation
    Date of revision of text on the SPC:   12/2006
    Legal Category:   prescription only

    Free-text change information supplied by the pharmaceutical company

    section 6.3
      Shelf life as packaged for sale:  increase from 2 to 3 years
     
     Additional text added for completeness:
     
    Shelf life after first opening:  The product should be used immediately after opening.

     Chemical and physical in-use stability has been demonstrated for both levobupivacaine 0.625 mg/ml and 1.25 mg/ml with 8.3-8,4 mg/ml clonidine, 50 mg /ml morphine and 2 mg /ml fentanyl, respectively, stored for 30 days at either 2-8ºC or 20–22°C.  Chemical and physical in-use stability has been demonstrated for both levobupivacaine 0.625 mg/ml and 1.25 mg/ml with sufentanil added in the concentration of 0.4 mg /ml and stored for 30 days at 2-8ºC or 7 days at 20–22°C.

     From a microbiological point of view, the product should be used immediately after opening.  If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8ºC, unless the admix has been prepared in controlled and validated aseptic conditions.

    Updated on 13/09/2006 and displayed until 19/12/2006
    Reasons for adding or updating:
    • New SPC for medicines.ie

    Document Links

     
      View all medicines
    from this company
    View Document
    Bookmark and Share

    Active Ingredients

     
       levobupivacaine hydrochloride

    Versions

     
    17/11/2011 to Current
    23/07/2010 to 17/11/2011
    05/10/2009 to 23/07/2010
    21/05/2007 to 05/10/2009
    19/12/2006 to 21/05/2007
    13/09/2006 to 19/12/2006
    • Terms & Conditions | 
    • Accessibility | 
    • Privacy Statement | 
    • Contact Us

    Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
    Registered Number: 254776
    Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

    This website is certified by Health On the Net Foundation. Click to verify.

    This site complies with the HONcode standard for trustworthy health information: verify here.

    logo